1. Cancelled.

2. Cancelled.

3. Cancelled.

4. Cancelled.

5. Cancelled.

6. Cancelled.

7. Cancelled.

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. Cancelled.

11. Cancelled.

12. Cancelled.

13. Cancelled.

14. Cancelled.

15. Cancelled.

16. A process for preparing a compound of Formula XI




**FORMULA XI**

RECEIVED
SEP 11 2003
TECH CENTER 1600/2900

($R_{16}$ = -$CH_2F$ or -$CH_2F_2$) by reacting a compound of Formula IX



**FORMULA IX**

with sodium borohydride to produce a compound of Formula X



**FORMULA X**

and further reacting this compound with diethylamino sulfurtrifluoride to produce compound of Formula XI.

17. A process for preparing a compound of Formula XII



**FORMULA XII**

wherein $R_{17}$ =  which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



**FORMULA IX**

with hydroxylamine.

18. A process for preparing a compound of Formula XII



**FORMULA XII**

wherein $R_{17}$ =  which comprises reacting (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide with hydrazine hydrate.

19. A process for preparing a compound of Formula XII



**FORMULA XII**

wherein $R_{17}$ =  which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with isocyanate.

20. A process for preparing a compound of Formula XII



**FORMULA XII**

**wherein $R_{17}$ = CN which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with trifilic anhydride and triethylamine.**

21. A process for preparing a compound of Formula XII



**FORMULA XII**

wherein R17 =  which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with 1,3-propane diol and $BF_3$ etherate.

22. A process for the preparation of the compound of Formula XIV



**FORMULA XIV**

wherein $R_{18}$ =  which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



**FORMULA IX**

with $Ag_2O$ to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII



**FORMULA XIII**

with aqueous ammonia to produce Formula XIV.

23. A process for the preparation of the compound of Formula XIV



**FORMULA XIV**

wherein $R_{18}$ = 

which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



**FORMULA IX**

with $Ag_2O$ to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII



**FORMULA XIII**

with thionyl chloride to produce Formula XIV.

24. A process for the preparation of the compound of Formula XIV



**FORMULA XIV**

wherein $R_{18}$ = 

which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



**FORMULA IX**

with $Ag_2O$ to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII




**FORMULA XIII**

with morpholine in the presence of oxalyl chloride to produce Formula XIV.

25. (New) A compound having the structure of Formula I




**FORMULA I**

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein

**T** is five- to seven-membered heterocyclic ring, aryl, substituted aryl, bound to the ring **C** with a linker **W** and the heterocyclic and aryl rings are further substituted by a group represented by **R**,

wherein R is selected from the group consisting of alkyl ($C_{1-6}$), halogen–CN, $COR_5$,$COOR_5$, $N(R_6,R_7)$, CON ($R_6$, $R_7$), $CH_2NO_2$, $NO_2$, $CH_2R_8$, $CHR_9$, -CH = N-$OR_{10}$, -C=CH-$R_5$, wherein $R_5$ is selected from the group consisting of H, optionally substituted $C_1$-$C_{12}$, alkyl, $C_{3-12}$, cycloalkyl, aryl, heteroaryl; $R_6$ and $R_7$ are independently selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy; $R_8$ and $R_9$ are independently selected from the group consisting of H, $C_{1-6}$ alkyl, F, Cl, Br, $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I, $OR_4$, $SR_4$, $N(R_6,R_7)$ wherein $R_4$ is selected from the group consisting of H, $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$

alkoxy, $C_{1-6}$ alkyl substituted with one or more F, Cl, Br, I or OH and $R_6$ and $R_7$ are the same as defined earlier, $R_{10}$ is selected from the group consisting of H, optionally substituted from H, optionally substituted $C_{1-12}$ alkyl, $C_{3-512}$ cycloalkyl, $C_{1-6,}$ alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl;

n is 1;

**X** is N

**Y and Z** are independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, and $C_{3-12}$ cycloalkyl;

**U and V** are independently selected from the group consisting of hydrogen, optionally substituted $C_{1-6}$ alkyl , F, Cl, Br, and $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I;

**W** is selected from the group $CH_2$, CO, $CH_2NH$, $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N$ ($R_{11}$) $CH_2$ -, -CO-CO-, $CH_2$ ( $R_{11}$) N -, CH ( $R_{11}$), S, $CH_2$( CO), N ($R_{11}$) wherein $R_{11}$ is hydrogen, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, aryl or heteroaryl;

**$R_1$** is selected from the group consisting of - $NHC(=O)R_2$ wherein $R_2$ is hydrogen, $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl substituted with one or more of F, Cl, Br, I or OH; $N(R_3, R_4)$; $-NR_2C(=S)R_3$; $-NR_2C(=S)SR_3$ wherein $R_2$ is the same as defined above and $R_3$ and $R_4$ are independently selected from the group consisting of H, $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl substituted with one or more of F, Cl, Br, I or OH.

26. (New) A compound having structure of Formula II




**FORMULA II**

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein

**M= O, S, NH, N-$CH_3$;**

**X** is N;

**Y and Z** are independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, and $C_{3-12}$ cycloalkyl;

**U and V** are independently selected from the group consisting of hydrogen, optionally substituted $C_{1-6}$ alkyl, F, Cl, Br, and $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I;

**W** is selected from the group consisting of $CH_2$, CO, $CH_2NH$, -$NHCH_2$, -$CH_2NHCH_2$, -$CH_2$-N ($R_{11}$) $CH_2$ - , $CH_2$ ( R11) N -, CH ( $R_{11}$) , S, $CH_2$( CO), NH wherein $R_{11}$ is optionally substituted with C $_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, C $_{1-6}$ alkyl , aryl , heteroaryl except when M=S, Q=P=H, W=(C=O);

**n** is 1; and,

**Q and P** are independently selected from the group consisting of -CN, $COR_5$, $COOR_5$, N ($R_6$, $R_7$), CON ($R_6$,$R_7$), $CH_2NO_2$, $NO_2$, $CH_2R_8$, $CHR_9$, -CH=N-$OR_{10}$, C=CH-$R_5$, wherein $R_5$ is selected from the group consisting of H, optionally substituted $C_{1-12}$alkyl, $C_{3-12}$ cycloalkyl, aryl, heteroaryl; $R_6$ and $R_7$ are independently selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy; $R_8$ and $R_9$

are independently selected from the group consisting of H, $C_{1-6}$ alkyl ,F, Cl, Br, $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I, $OR_4$, $SR_4$, wherein $R_4$ is selected from the group consisting of H, $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl substituted with one or more F, Cl, Br, I or OH, $N(R_6, R_7)$, $R_{10}$ is selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl except W= (CO), Q and P =H and M=S, wherein M = Sulphur and Oxygen as shown by Formulae III and IV respectively,




**FORMULA III**




**Formula IV**

wherein **P, Q, U, V, X , Y, Z, W and n** in Formulae **III** and IV as defined earlier for Formula I.

27. (New) A compound selected from the group consisting of

1. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furoyl) piperazinyl]]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
2. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

3. (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

4. (S)-N-[[3-Fluoro-4-[N-1[4-(5-bromo-2-furoyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

5. (S)-N-[[3-Fluoro-4-[N-1[4-(5-chloromethyl-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

6. (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

7. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-(2-thienyl)dicarbonyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

8. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl] acetamide

9. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-bromo)methyl}]piperazinyl]phenyl ]2-oxo-5-oxazolidinyl]methyl]acetamide

10. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-chloro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

11. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

12. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-thienylmethyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

13. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

14. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(4-bromo)methyl}]piperazinyl] phenyl]-2 oxo-5-oxazolidinyl]methyl]acetamide

15. (S)-N-[[3-[3-fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

16. Hydrochloric salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

17. Citrate salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

18. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-pyrrolylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

19. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(3-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

20. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

21. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

22. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-pyrrole(1-methyl)methyl}]piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

23. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

24. (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-thiomorpholinyl)methyl}methyl]piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

25. (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-morpholinyl)methyl}methyl]]piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

26. (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-acetoxymethyl)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

27. (S)-N-[[3-Fluoro-4-[N-1[4-{2-thienyl(5-bromo)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

28. (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furylmethyl)piperazinyl] phenyl]- 2-oxo oxazolidinyl]methyl]dichloroacetamide

29. (S)-N[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride

30. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2',2'- diphenyl-2' hydroxy acetyl )] piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

59. (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl) methyl] piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.

60. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

61. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate) methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

62. (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

63. (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl) methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

64. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

65. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate) methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

66. (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

67. (S)-N-[[3-[3-Fluoro-4-[N-1{2-furyl-[4-(5-hydroxymethyl)methyl}] piperazinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

68. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}] piperazinyl]phenyl] -2-oxo-5-oxazolidinyl]methyl]acetamide

69. (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

70. (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

71. (S)-N-[[3-Fluoro-4-[N-1[5-(formamido)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

72. (S)-N-[[3-Fluoro-4-[N-1[5-(morpholine-1-carbonyl)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

73. (S)-N-[[3-Fluoro-4-[N-1[5-(4-(tert butoxy carbonyl)amino piperidine)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

74. (S)-N-[[3-Fluoro-4-[N-1[4-{(Z)-2-methoxyimino-2-(2-furyl)acetyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

28. (New) A pharmaceutical composition comprising the compound of claims 25, 26, or 27 and a pharmaceutically acceptable carrier.

29. (New) A pharmaceutical composition comprising a pharmaceutically effective amount of compound according to claims 25, 26 or 27, or a physiologically acceptable acid addition salt thereof with a pharmaceutically acceptable carrier for treating microbial infections.

30. (New ) A method of treating or preventing microbial infections in a mammal comprising administering to the said mammal, the pharmaceutical composition according to claim 29.

31. (New ) A process for preparing a compound of Formula I




**FORMULA I**

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein

**T** is five to seven membered heterocyclic ring, aryl, substituted aryl, bound to the ring **C** with a linker w and the heterocyclic and aryl rings are further substituted by a group represented by **R**,

wherein R is selected from the group consisting of –CN, $COR_5$,$COOR_5$, $N(R_6,R_7)$, CON ($R_6$, $R_7$), $CH_2NO_2$, $NO_2$, $CH_2R_8$, $CHR_9$, -CH = N-$OR_{10}$, -C=CH-$R_5$, wherein $R_5$ is selected from the group consisting of H, optionally substituted $C_1$-$C_{12}$, alkyl, $C_{3-12}$, cycloalkyl, aryl, heteroaryl, $R_6$ and $R_7$, are independently selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy; $R_8$ and $R_9$ are independently selected from the group consisting of H, $C_{1-6}$ alkyl, F, Cl, Br, $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I, $OR_4$, $SR_4$, $N(R_6,R_7)$ wherein $R_4$ is selected from the group consisting of H, $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl substituted with one or more F, Cl, Br, I or OH and $R_6$ and $R_7$ are the same as defined earlier, $R_{10}$ is selected from the group consisting of H, optionally substituted from H, optionally substituted $C_{1-12}$ alkyl, $C_{3-512}$ cycloalkyl, $C_{1-6}$, alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl;

**n** is 1;

**X** is N;

**Y and Z** are independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, and $C_{3-12}$ cycloalkyl;

**U and V** are independently selected from the group consisting of hydrogen, optionally substituted $C_{1-6}$ alkyl, F, Cl, Br, and $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I;

**W** is selected from the group consisting of $CH_2$, CO, $CH_2NH$, $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2$-N ($R_{11}$) $CH_2$ -, $CH_2$ ( R11) N-, CH ( $R_{11}$), S, $CH_2$( CO), NH wherein $R_{11}$ is optionally substituted with $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl; and

**$R_1$** is selected from the group consisting of - $NHC(=O)R_2$ wherein $R_2$ is hydrogen, $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl substituted with one or more of F, Cl, Br, I or OH; $N(R_3, R_4)$ ; $-NR_2C(=S)$ $R_3$ : $-NR_2C(=S)SR3$ wherein $R_2$ is the same as defined above and $R_3$ and $R_4$ are independently selected from the group consisting of H, $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl substituted with one or more of F, Cl, Br, I or OH,

which comprises reacting an amine compound of Formula V




**FORMULA V**

with a heterocyclic compound of Formula R-T-W- $R_{12}$ wherein G in amines of

Formula V is defined as NH and Y, Z, U, V, $R_1$, n, R, T and W are the same as defined earlier and $R_{12}$ is a leaving group selected from the group consisting of fluoro, chloro, bromo, $SCH_3$, -$SO_2CH_3$, -$SO_2CF_3$ or $OC_6H_5$.

32. (New) A process for preparing a compound of Formula I as claimed in claim 31, wherein W=$CH_2$ and R-T-W-$R_{12}$ is a five membered heterocyclic ring with aldehyde group and the compound of Formula I is produced by reductive amination.

33. (New) A process for preparing a compound of Formula I as claimed in claim 31, wherein W = CO and R-T-W-$R_{12}$ is a five membered heterocyclic ring with carboxylic acid, and amino compound of Formula V is acylated with activated esters in presence of condensing agents comprising 1,3-dicyclohexylcarbodiimide (DCC) and 1-(3-dimethylaminopropyl)-3-ethylcarbo-diimide (EDC).

34. (New) A process for the preparation of compound of Formula II




**FORMULA II**

wherein

**n** is 1;

**X** is N;

**Y and Z** are independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, and $C_{3-12}$ cycloalkyl;

**U and V** are independently selected from the group consisting of hydrogen, optionally substituted $C_{1-6}$ alkyl, F, Cl, Br, and $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I;

**W** is selected from the group consisting of $CH_2$, CO, $CH_2NH$, $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N(R_{11})CH_2-$, $CH_2(R11)N-$, $CH(R_{11})$, S, $CH_2(CO)$, NH wherein $R_{11}$ is optionally substituted with $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl; and

**Q and P** are independently selected from the group consisting of -CN, $COR_5$, $COOR_5$, $N(R_6, R_7)$, $CON(R_6,R_7)$, $CH_2NO_2$, $NO_2$, $CH_2R_8$, $CHR_9$, $-CH=N-OR_{10}$, $C=CH-R_5$, wherein $R_5$ is selected from the group consisting of H, optionally substituted $C_{1-12}$alkyl, $C_{3-12}$ cycloalkyl, aryl, heteroaryl; $R_6$ and $R_7$ are independently selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy; $R_8$ and $R_9$ are independently selected from the group consisting of H, $C_{1-6}$ alkyl,F, Cl, Br, $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I, $OR_4$, $SR_4$,wherein $R_4$ is the same as defined before, $N(R_6, R_7)$, $R_{10}$ is selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl except W= (CO), Q and P =H.

wherein M = Sulphur is shown by compounds of Formula III,




**FORMULA III**

wherein **P, Q, U, V, X, Y, Z, W and n** in Formula III are the same as previously defined, wherein the process comprising reacting a compound of Formula V




FORMULA V

with a compound of Formula VI




FORMULA VI

wherein P, Q, $R_{12}$, Y, Z, G, n, U and V are the same as defined earlier.

35. (New) A process for preparing a compound of Formula II as claimed in claim 34, in a solvent selected from the group consisting of dimethylformamide, dimethylacetamide, ethanol or ethylene glycol at a temperature in the range of -70°C to 180°C in the presence of a base selected from the group consisting of triethyl amine, diisopropyl amine, potassium carbonate and sodium bicarbonate.

36. (New) A process of preparing a compound of Formula II as claimed in claim 34, wherein Formula VI is furaldehyde and reductive alkylation of the amine of Formula V is performed with a reducing agent.

37. (New) A process for preparing a compound of Formula II as claimed in claim 34, wherein Formula VI is furoic acid.

38. (New) A process for preparing a compound of Formula II as claimed in claim 34, wherein the compounds of Formula II having carbonyl link are prepared by reacting a heteroaromatic compound of the Formula VI including N- methyl pyrrole with the intermediate amine of Formula V in the presence of triphosgene or phosgene and carbonyl linkers are introduced between heteroaromatic compound comprising reacting 3- bromothiophene and amine of Formula V with carbon monoxide and the catalyst is selected from the group consisting of Pd $(PPh_3)_2Cl_2$ and extended chain pyrroles having dicarbonyl linkers are obtained by treatment of oxalyl chloride and amine of the Formula V.

39. (New) A process for preparing a compound of Formula VIII




FORMULA VIII

wherein

**n** is 1;

**X** is N;

**Y and Z** are independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, and $C_{3-12}$ cycloalkyl;

**U and V** are independently selected from the group consisting of hydrogen, optionally substituted $C_{1-6}$ alkyl, F, Cl, Br, and $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I;

**W** is selected from the group consisting of $CH_2$, CO, $CH_2NH$, $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2$-N $(R_{11})$ $CH_2$ -, $CH_2$ ( R11) N-, CH ( $R_{11}$), S, $CH_2$( CO), NH wherein $R_{11}$ is

optionally substituted with $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl;

**Q and P** are independently selected from the group consisting of -CN, $COR_5$, $COOR_5$, N ($R_6$, $R_7$), CON ($R_6$,$R_7$), $CH_2NO_2$, $NO_2$, $CH_2R_8$, $CHR_9$, -CH=N-$OR_{10}$, C=CH-$R_5$, wherein $R_5$ is selected from the group consisting of H, optionally substituted $C_{1-12}$alkyl, $C_{3-12}$ cycloalkyl, aryl, heteroaryl; $R_6$ and $R_7$ are independently selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy; $R_8$ and $R_9$ are independently selected from the group consisting of H, $C_{1-6}$ alkyl,F, Cl, Br, $C_{1-12}$ alkyl substituted with one or more of F, Cl, Br, I, $OR_4$, $SR_4$,wherein $R_4$ is the same as defined before, N($R_6$, $R_7$), $R_{10}$ is selected from the group consisting of H, optionally substituted $C_{1-12}$ alkyl, $C_{3-12}$ cycloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, aryl, heteroaryl except W= (CO), Q and P =H;

M = Sulphur is shown by compounds of Formula III




**FORMULA III**

and $R_{15}$ is the same as Q defined earlier, comprising converting a compound of Formula VII




**FORMULA VII**

wherein in U, V, Y, Z, X, W, P, n and M are the same as defined earlier and are $R_{14}$ is any group which can be converted to group $R_{15}$ in one to five steps.